At EVOQ, our mission is clear. We are engineering new solutions to one of the world’s most urgent health threats: antimicrobial resistance. Since the beginning of the year, we have accelerated that mission with the support of a partner who understands the power of smart science and bold action.
On January 30, 2025, we announced a strategic investment from Tony Robbins, the world-renowned business strategist, philanthropist, and author. In addition to investing in our company, he joined our advisory board, and we are already seeing the positive effects of that partnership as we expand our antimicrobial technology and move closer to delivering life-saving solutions.
This collaboration came at a critical time. Antibiotic-resistant bacteria are spreading faster than new treatments can be developed. According to the World Health Organization, antimicrobial resistance is one of the top ten global health threats. That reality is driving demand for new approaches. For EVOQ, the answer lies in the power of metamaterial engineering.
Our lead asset is EVQ-218, a metamaterial that disables bacteria from the inside rather than rupturing the outer cell wall. This mechanism blocks bacterial metabolism without damaging human cells or triggering antimicrobial resistance.
EVQ-218 is characterized as a “new form of silver” by the American Chemical Society journal. Unlike conventional metamaterials that emit harmful ions, EVQ-218 is stable, non-ionic, and safe. It preserves the materials it is added to, and it has shown a more than 99.99 percent reduction in dangerous bacteria across a wide range of surfaces and applications.
We are applying this technology in three key sectors where bacterial contamination causes real-world harm:
- Therapeutics Our biotech division, EVOQ Bio, is developing an inhaled therapy using EVQ-218 to treat drug-resistant lung infections in people with cystic fibrosis. In partnership with the Cystic Fibrosis Foundation, we recently completed a successful pre-Investigational New Drug (pre-IND) meeting with the FDA. We are now preparing for Phase I clinical trials.
- Medical devices Healthcare-associated infections affect over one million U.S. patients every year. Through EVOQ MedTech, we are integrating EVQ-218 into medical devices such as catheters and fittings to offer built-in protection. We are currently working with leading manufacturers to move this work into clinical settings.
- Textiles and surfaces Our textile division, FUZE Technologies, delivers antimicrobial protection to hotels, gyms, offices, and athletic wear. Our F1 treatment, free of harsh chemicals, is used by Nike, Adidas, Marriott, Hilton, and the New England Patriots. It is safe, sustainable, and long-lasting.
Tony Robbins is known for identifying transformational ideas that create real impact. He saw the urgency of the problem and the strength of our scientific solution.
At the time of the announcement, Mr. Robbins said:
“I’ve always looked to support advancements in health technology, and EVOQ’s approach to fighting antibiotic-resistant bacteria addresses an urgent global challenge. This technology has the potential to save millions of lives and transform how we approach infection prevention and treatment.”
His support has helped amplify our message, expand our network, and strengthen our business strategy. His involvement on our advisory board has added a valuable new perspective as we grow.
In the months since the announcement, our work has continued to expand. We are moving our inhaled therapy closer to clinical trials, advancing our medical device partnerships, and broadening the use of FUZE across industries.
We are also exploring additional applications. In energy, EVQ-218 may help prevent corrosion and extend battery life. In agriculture, it could support crop protection and food safety. In infrastructure, it may offer cleaner, longer-lasting alternatives to traditional chemical treatments.
The versatility of our metamaterial platform makes it possible to apply one core technology across many essential sectors.
Our goal has always been to bring real-world impact through advanced science. The investment and strategic partnership from Tony Robbins reflect a shared belief in the importance of that goal. Together, we are building not just a company, but a movement to rethink how materials can protect human health.
We are proud of the progress we have made thus far, and even more excited about what is ahead.